Retroperitoneal Sarcoma Registry (RESAR): prospective collection of patient data and radiological and pathological material for the TransAtlantic Retroperitoneal Sarcoma Working Group

International collection of data, imaging material and pathological material from patients with primary retroperitoneal sarcoma.

Retroperitoneal sarcomas are rare tumours that arise in the space behind the abdominal cavity. Because of the rarity of the disease, linking data from several specialised centres is important for improving knowledge and treatment. RESAR is a prospective, multicentre observational study conducted within an international working group for retroperitoneal sarcoma.

Purpose of the study

The purpose of the study is the standardised collection of clinical data and radiological and pathological material from patients with primary retroperitoneal sarcoma. The collected data will enable analysis of treatment outcomes, survival, disease recurrence and distant metastases, and will contribute to better understanding of the disease and development of more appropriate treatment approaches.

Study procedure

The study does not change usual treatment. If the patient decides to participate, data on the disease, treatment, imaging examinations, pathological characteristics of the tumour and follow-up are included in the research database. After treatment, patients attend regular follow-up visits and imaging examinations according to the planned follow-up protocol. Data are processed confidentially and in pseudonymised form.

Who can take part?

Patients with primary retroperitoneal sarcoma for whom surgical management or treatment at a reference centre is planned and who meet the study inclusion criteria.

How to apply?

The patient will be informed about the possibility of participation by a physician. Before inclusion, the patient receives information about the study and signs informed consent. Participation is voluntary and may be withdrawn at any time without affecting further healthcare. For additional information, please contact your treating physician or the study staff by email: [email protected].